Abstract:Genetic research on Alzheimer′s disease (AD) has primarily focused on amyloid-β (Aβ) pathogenesis, with fewer studies exploring tau pathology. Elucidating the genetic basis of tau pathology could identify novel pathways in AD. We conducted a genome-wide association study of tau standard uptake value ratios (SUVRs) from [18]F-flortaucipir positron emission tomography (PET) images to identify genetic variants underlying Tau pathology. Genetic data and tau-SUVRs from [18]F-flortaucipir PET images were acquired from the A4 (311 with preclinical AD) and ADNI (280 cognitively normal, 76 with mild cognitive impairment, and 19 AD patients) studies. Circulating plasma proteins in UK Biobank Pharma Proteomics Project (UKBPPP, N=54,129) were used to validate genetic findings. SNP genotypes were tested for association with Tau-SUVR levels adjusting for age, sex and population substructure variables. AD association of polygenic risk scores (PRS) of tau and amyloid-SUVRs were assessed. Causal effect of plasma protein levels on Tau pathology were tested using Mendelian randomization analyses. GWAS of tau-SUVR revealed two significant loci: rs78636169 ( =5.76×10 ) in and rs7292124 ( =2.20×10 ) near . Gene-based analysis of tau deposition highlighted APOE ( =2.55×10 ), CTNNA3 ( =2.86×10 ) and ( =1.23×10 ), a component of the PRC2 multi-protein complex which regulates gene expression. Mendelian randomization analysis of available circulating plasma proteins in the UK Biobank Pharma Proteomics Project (UKBPPP) identified LRRFIP1, a protein that binds with PRC2 multi-protein complex, as potentially causally linked to tau pathology. Genes associated with both amyloid and tau pathologies were enriched in endocytosis and signal transduction pathways. AD polygenic risk score (PRS) was associated with amyloid-SUVR but not with tau-SUVR. Amyloid-SUVR PRS had a notable association with AD clinical status, particularly in younger -ϵ4 carriers, whereas tau-SUVR PRS showed a stronger association in older carriers. We identified a novel potential therapeutic target, in the PRC2 multi-protein complex, for tau pathology. Furthermore, gene pathway analysis clarified the distinct roles of Aβ and tau in AD progression, underscoring the complexity of genetic influences across different stages of the disease.

A Pathway-Specific Polygenic Risk Score Is Associated with Tau Pathology and Cognitive Decline

Association of Polygenic Risk Score with Age at Onset and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease in a Chinese Cohort

Association of polygenic risk scores with Alzheimer's disease and plasma biomarkers among Chinese older adults: A community‐based study

Polygenic Risk Score Reveals Genetic Heterogeneity of Alzheimer’s Disease between the Chinese and European Populations

Prediction of clinical diagnosis of Alzheimer’s disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years

Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer’s Disease

The effect of polygenic risk on white matter microstructural degeneration in Parkinson's disease: A longitudinal Diffusion Tensor Imaging study

Polygenic hazard score modified the relationship between hippocampal subfield atrophy and episodic memory in older adults

Polygenic Hazard Score Associated Multimodal Brain Networks along the Alzheimer's Disease Continuum.

Association of whole-person eigen-polygenic risk scores with Alzheimer's disease

Polygenic Risk Scores in Alzheimer’s Disease Genetics: Methodology, Applications, Inclusion, and Diversity

Polysocial and Polygenic Risk Scores and All-Cause Dementia, Alzheimer's Disease, and Vascular Dementia.

Comparison of subjective cognitive decline and polygenic risk score in the prediction of all-cause dementia, Alzheimer's disease and vascular dementia

PTPRS is a novel marker for early Tau pathology and synaptic integrity in Alzheimer’s disease

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.

Novel Genetic Variants in TP37, PIK3R1, CALM1, and PLCG2 of the Neurotrophin Signaling Pathway Are Associated with the Progression from Mild Cognitive Impairment to Alzheimer's Disease

PTPRS is a novel marker for early tau pathology and synaptic integrity in Alzheimer's disease

Genome-wide scan of Flortaucipir PET levels finds associated with cerebral tau deposition

Polygenic risk associated with Alzheimer's disease and other traits influences genes involved in T cell signaling and activation

A polygenic risk score for Alzheimer’s disease determines the risk of incident dementia in APOE ɛ4 negative individuals over the age of 95: A population‐based cohort study

Polygenic risk score penetrance & recurrence risk in familial Alzheimer disease